Average deductibles for Obamacare bronze plans will top $6,000 for individuals for the first time next year. » Read More
Michael Neidorff, Centene chairman & CEO, says he is pleased with the way Obamacare has worked out for his company despite the exit of big insurers like Aetna and Humana from the exchange. » Read More
Ten million people are projected to have coverage from government health exchanges by the end of 2016, a modest increase.
A strong majority say the Affordable Care Act will play an important role in their vote.
There was a drop in the number of patients seen by doctors, who still had increased payments.
Many companies at risk of the tax on high-cost health plans intend to avoid the levy.
Doctors outside of insurance plan networks charge several times what Medicare would pay.
Most companies now offer health coverage that requires employees to pay an annual deductible before insurance kicks in, and the size of that deductible has soared in the past decade, a study finds.
Bankers Life recently ranked 60 U.S. metro areas in order of health and affordability for retirees. A look at the top 10 cities.
The current number of Obamacare sign-ups is still ahead of an official 9.1 million customer year-end goal.
Nonprofit health insurer Blue Shield of California increased its executive compensation by 64 percent in 2012, according to a report.
The 40 percent tax on high-cost health plans is expected to hit 26 percent of employers in 2018
A series of new studies out this week shows solid progress toward a flu vaccine in a pill and a so-called universal flu vaccine. NBC News reports.
Brace yourself for some big changes in 2018 if the so-called Obamacare Cadillac tax isn't changed.
What's driving insurance rate increases, with Tenet Healthcare President & CEO Trevor Fetter.
Employers face a set of complex, and potentially expensive, regulations under Obamacare.
Life insurers are offering more products that will cover long-term care costs. Here's why.
Shire, the specialty pharma company, may need to find an antidote for a poison pill before it can win shareholders in Baxalta over to its $30bn bid.
Get the best of CNBC in your inbox